Aldolase A as a prognostic factor and mediator of progression via inducing epithelial–mesenchymal transition in gastric cancer

Zhonghua Jiang1 | Xiaohong Wang2 | Jing Li3 | Hongmei Yang1 | Xin Lin4

1Department of Gastroenterology, The First People’s Hospital of Yancheng, Yancheng, China
2Department of Gastroenterology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
3Departments of CyberKnife, Huashan Hospital, Fudan University, Shanghai, China
4Department of Digestive Endoscopy, The First People’s Hospital of Wujiang District, Suzhou, China

Correspondence
Zhonghua Jiang and Hongmei Yang
Emails: jiangzhonghua1982@163.com (ZJ) and 196206yhm@163.com (HY)

Abstract
Glycolysis is regarded as the hallmark of cancer development and progression, which involves a multistep enzymatic reaction. This study aimed to explore the clinico-pathological significance and potential role of glycolytic enzyme aldolase A (ALDOA) in the carcinogenesis and progression of gastric cancer (GC). ALDOA was screened from three paired liver metastasis tissues and primary GC tissues and further explored with clinical samples and in vitro studies. The ALDOA protein level significantly correlated with a larger tumor diameter \((P = .004)\), advanced T stage \((P < .001)\), N stage \((P < .001)\) and lymphovascular invasion \((P = .001)\). Moreover, the expression of ALDOA was an independent prognostic factor for the 5-year overall survival and disease-free survival of patients with GC in both univariate and multivariate survival analyses \((P < .05)\). Silencing the expression of ALDOA in GC cell lines significantly impaired cell growth, proliferation and invasion ability \((P < .05)\). Knockdown of the expression of ALDOA reversed the epithelial–mesenchymal transition process. Mechanically, ALDOA could affect the hypoxia-inducible factor (HIF)-1\(\alpha\) activity as demonstrated by the HIF-1\(\alpha\) response element–luciferase activity in GC cells. Collectively, this study revealed that ALDOA was a potential biomarker of GC prognosis and was important in the carcinogenesis and progression of human GC.

KEYWORDS
ALDOA, epithelial–mesenchymal transition, gastric cancer, survival analysis

1 | INTRODUCTION

Gastric cancer (GC) is one of the most common and deadliest malignancies worldwide, especially in East Asia.\(^1\) Despite recent advancements in diagnosis and therapeutic methods, the prognosis of GC is still poor and the 5-year survival rate for patients with GC has remained 20%-25%\(^2\).\(^3\) The survival of patients largely depends on the disease stage at diagnosis. The tumour-node-metastasis staging system has been widely used as an effective approach to predict the prognosis of and determine the treatment option for GC. However, the challenges of considerable prognostic heterogeneity within each tumour stage need to be faced, as tumours at the same pathological stage can produce considerably different clinical outcomes,\(^4\)\(^-\)\(^7\) highlighting the urgency for identification of other factors, such as the molecular mechanisms that influence metastases and prognosis of GC. Identifying biomarkers for early diagnosis and progression could
help explain the biochemical mechanism underlying the processes of metastasis and progression as well as therapeutic sensitivity.

Tumour cells proliferate at a rapid rate and are always in a hypoxic microenvironment. Cancer cells develop adaptive responses to hypoxia by activating the hypoxia-inducible genes to overcome this harsh environment. Under this circumstance, hypoxia is a major characteristic of cancer; in hypoxic conditions, cancer cells develop metabolism reprogram from oxidative phosphorylation to glycolysis. A feature of this phenomenon is increased lactate production even at normal oxygen concentrations. This phenomenon is named as the Warburg effect or aerobic glycolysis. The Warburg effect was considered to be at the root of carcinogenesis and progression. It not only provides cancer cells with adenosine triphosphate (ATP) and nutrients but also leads to an acidic environment that facilitates metastasis.

In this study, quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR) arrays of glycolysis-related enzymes were performed in three paired liver metastasis tissues and primary GC tissues. Aldolase A (ALDOA) was chosen for further study. This study mainly investigated the expression of ALDOA in GC tissues and its clinical significance and biological function in GC cells and also elucidated the mechanisms underlying the regulatory role of ALDOA in GC cells.

2 MATERIALS AND METHODS

2.1 Patients and samples

A series of 252 patients with pathologically confirmed GC was used for the immunohistochemical (IHC) study to explore the clinical significance of the expression of ALDOA in GC. All patients who had no neoadjuvant chemotherapy and received radical gastrectomy were randomly selected from samples collected between 2008 and 2012. The median follow-up time was 46 months. The characteristics of the samples are shown in Table 1.

This study was performed in compliance with the Helsinki Declaration. The use of clinical samples was approved by the Human Ethics Review Committee of the First People’s Hospital of Yancheng, Yancheng, China. Written informed consent was obtained from all patients included in the study.

2.2 Cell lines

Human gastric adenocarcinoma cell lines, AGS and MGC-803, were originally obtained from the Institute of Biochemistry and Cell Biology at the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in the Dulbecco’s modified Eagle’s medium containing 10% foetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin in a 37°C incubator supplied with 5% CO₂.

2.3 Western blot analysis

Protein extracts (50 mg) were resolved on 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis gels, transferred to nitrocellulose membranes (0.45 mm), and immunoblotted with rabbit anti-
human ALDOA antibody (11217-1-AP; 1:1000; Proteintech), anti-E-cadherin antibody (ab40772; 1:1000; Abcam), anti-N-cadherin antibody (ab18203; 1:1000; Abcam), anti-Vimentin (ab92547; 1:1000; Abcam) or mouse anti-human β-actin monoclonal antibody (ab133626; 1:1000; Abcam). Images were developed using ECL (Pierce, Thermo Scientific, USA).

2.4 | qPCR

The total RNA was extracted from cell lines using the TRIzol reagent (Invitrogen, CA, USA). qRT-PCR was performed using the RNA PCR kit (TaKaRa, Dalian, China) and Fast SYBR Green qPCR Master Mix on Mx3000P (Stratagene, CA, USA) according to the manufacturer’s protocol. The expression of β-actin was used as an internal control. The primer sequence used was ALDOA-F: ATGCCCTACCAATATCCAGCA and ALDOA-R: GCTCCCAGTG-GACTCATCTG.

2.5 | IHC staining

Immunohistochemical staining was performed for ALDOA. Briefly, paraffin sections were baked for 60 minutes at 70°C, deparaffinized in xylene and rehydrated in gradually varied alcohol. Then, the sections were managed with 3% H2O2 to neutralize endogenous peroxidase for 30 minutes. The antigen retrieval was processed with citrate buffer (pH = 6.0) in a pressure cooker. After antigen retrieval, the sections were incubated with ALDOA primary antibody (11217-1-AP; 1:100; Proteintech) and secondary antibody. The sections were then stained with 3,3-diaminobenzidine, terminated in phosphate-buffered saline (PBS), and counterstained with haematoxylin. Based on the staining intensity of ALDOA in each case, the grading was as follows: 0, negative; 1, weak; 2, moderate; and 3, strong. The scores 0 and 1 were regarded as low expression and 2 and 3 as high expression. Two observers graded the score of staining intensity independently.

2.6 | Stable transfection of GC cells

Biologically active short hairpin RNAs (shRNA) were generated using the lentiviral expression vector pLKO.1-puro. The shRNA target sequence for human ALDOA was 5′-CCATGCTTGCACTCAGAAGTT-3′. pLKO.1-scramble shRNA with limited homology having any known sequences in the human, mouse and rat genomes was used as a negative control. AGS and MGC803 cells were transfected with the pLKO.1-shALDOA expression vector or pLKO.1-scramble. The cells stably transfected were isolated using puromycin selection to obtain stable ALDOA knockdown cells.

2.7 | Cell Counting Kit-8 assays

The cells were seeded at a density of 2000 cells/well in 96-well plates and incubated. An aliquot of 10 μL of Cell Counting Kit-8 solution (CCK-8; Dojindo, Kumamoto, Japan) was added to the wells and incubated for 2 hours. The absorbance was measured at 450 nm to calculate the numbers of viable cells in each well. Each measurement was performed in triplicate, and the experiments were repeated twice.

2.8 | Colony formation assays

The cells were trypsinized and plated on six-well plates (200 cells/well) and cultured for 2 weeks. The colonies were stained with 1% crystal violet for 30 seconds after fixation with 4% paraformaldehyde for 5 minutes. The colonies were counted and defined as >50 cells/colony. Three independent experiments were performed. The data were calculated using paired t test.

2.9 | Transwell migration

Cell invasion assays were performed using 6.5-mm Transwell chambers (8-μm pore size, BD). The cells were seeded at a density of 50 000 cells/well into Transwell chambers coated with Matrigel for assays. The wells were washed with PBS after 36 hours of seeding.
The cells that had migrated to the basal side of the membrane were fixed and stained with crystal violet, visualized and photographed using a CKX41 microscope (Olympus, Japan) at 200× magnification. Images of three random fields from three replicate wells were obtained, and the cells that had migrated were counted.

2.10 | Statistical analysis

Comparisons between groups for statistical significance were performed with a two-tailed paired Student’s t test. The relationship between the expression of ALDOA and clinicopathological features was analyzed using the χ² test.
characteristics was tested using the chi-square test. Survival curves were plotted by the Kaplan–Meier method and compared using the log-rank test. The significance of various survival-related variables was assessed using the Cox regression model in multivariate analysis. All statistical analyses were performed using the SPSS 17.0 statistical software package. A $P$ value $<.05$ was considered statistically significant.

3 | RESULTS

3.1 | Glycolytic enzyme ALDOA might promote tumor metastasis in GC

Glycolysis is a process involving a series of glycolytic enzymes. The qRT-PCR assay was performed and the transcriptional expression levels of glycolytic enzymes in three paired GC tissues, and their paired synchronous liver metastasis tissues were measured to identify the glycolytic enzymes involved in gastric cancer metastasis. All patients underwent synchronous primary tumour and liver metastases resection. The results indicated that the up-regulated expression of ALDOA and down-regulated FBP1 were most significant in liver metastases compared with its primary tumour (Figure 1). As FBP1 has been studied previously, $^{18}$ ALDOA was chosen for further study.

3.2 | ALDOA was overexpressed in GC tissues

Quantitative reverse transcriptase–polymerase chain reaction and IHC staining were performed on 30 pairs of GCs (T) and matched adjacent gastric tissues (N) to explore whether ALDOA was dysregulated in human GC. As shown in Figure 2A, the mRNA expression of ALDOA increased 4.42- to 6.94-fold in the GC tissues compared

| TABLE 2 | Univariate and multivariate Cox proportional hazards analyses of the expression of ALDOA gene and overall survival for patients with gastric cancer |
| Factor | Univariate analysis | Multivariate analysis |
| | HR (95% CI) | $P$ | HR (95% CI) | $P$ |
| Gender | 0.780 (0.514-1.183) | .242 |  |
| Age | 1.262 (0.832-1.915) | .273 |  |
| Diameter | 1.254 (0.810-1.941) | .309 |  |
| T stage | 2.029 (1.479-2.782) | <.001 | 1.267 (0.824-1.949) | .281 |
| N stage | 1.652 (1.365-2.000) | <.000 | 1.442 (1.124-1.850) | .004 |
| Grade | 1.694 (1.094-2.625) | .018 | 1.179 (0.752-1.848) | .474 |
| Lymphovascular invasion | 2.193 (1.404-3.426) | .001 | 1.469 (0.923-2.336) | .104 |
| Perineural invasion | 1.835 (1.193-2.822) | .006 | 1.813 (1.163-2.825) | .009 |
| Tumor location | 1.149 (0.957-1.379) | .137 |  |
| ALDOA | 3386 (1.909-6.008) | <.001 | 2.596 (1.440-4.680) | .002 |

CI, confidence interval; HR, hazard ratio. Bold type indicates statistical significance.

| TABLE 3 | Univariate and multivariate Cox proportional hazards analyses of the gene expression of ALDOA and disease-free survival for patients with gastric cancer |
| Factor | Univariate analysis | Multivariate analysis |
| | HR (95% CI) | $P$ | HR (95% CI) | $P$ |
| Gender | 0.949 (0.662-1.361) | .775 |  |
| Age | 1.132 (0.789-1.624) | .500 |  |
| Diameter | 1.187 (0.814-1.729) | .373 |  |
| T category | 2.068 (1.568-2.728) | <.001 | 1.504 (1.056-2.141) | .024 |
| N stage | 1.477 (1.260-1.732) | <.001 | 1.218 (1.001-1.483) | .049 |
| Grade | 1.917 (1.302-2.822) | .001 | 1.447 (0.975-2.149) | .067 |
| Lymphovascular invasion | 2.205 (1.497-3.248) | <.001 | 1.489 (0.992-2.235) | .055 |
| Perineural invasion | 1.503 (1.022-2.211) | .038 | 1.388 (0.935-2.061) | .104 |
| Tumor location | 1.069 (0.910-1.257) | .416 |  |
| ALDOA | 3.722 (2.221-6.236) | <.001 | 2.824 (1.667-4.783) | <.001 |

CI, confidence interval; HR, hazard ratio. Bold type indicates statistical significance.
with their matched adjacent cervical tissues. As expected, the protein expression of ALDOA was also markedly up-regulated in the GC tissues as judged by IHC (Figure 2B,C).

### 3.3 Expression of ALDOA correlated with inferior clinicopathological parameters

Immunohistochemistry of a series of 252 patients with primary GC was performed, including 134 males and 118 females with a mean age of 59 years (range, 21-85 years), to investigate the clinicopathological significance of the expression of ALDOA. Of the 252 specimens, the expression of ALDOA was mainly observed in the cytoplasm in the majority of gastric cancerous specimens, with strong expression in 178 (70.6%) patients and weak or negative expression in 74 (29.4%) patients. Associations between the clinicopathological factors and the expression of ALDOA are summarized in Table 1. The increased expression of ALDOA significantly correlated with the depth of tumour invasion (T stage, \( P < .001 \)), lymph node metastasis (N stage, \( P < .001 \)), lymphovascular invasion (\( P = .001 \)) and tumour diameter (\( P = .004 \)) (Table 1). The factors not significantly associated with the staining included age (\( P = .672 \)), sex (\( P = .197 \)), primary tumour site (\( P = .076 \)) and perineural invasion (\( P = .250 \)).

### 3.4 Expression of ALDOA significantly correlated with survival outcomes in GC

This study further evaluated the relationship between the expression of ALDOA protein and the 5-year overall survival (OS) or
disease-free survival (DFS) of patients. The results revealed a worse OS in patients with higher expression of ALDOA (high vs low expression: 39.2% vs 76.9%, \( \chi^2 = 19.635, P < .001 \)) (Figure 3A). Similarly, a shorter DFS was also found in patients with a higher expression of ALDOA (high vs low expression: 33.0% vs 70.9%, \( \chi^2 = 28.857, P < .001 \)) (Figure 3B). Moreover, multivariate survival analysis demonstrated that the expression of ALDOA was an independent prognostic factor for both OS (hazard ratio [HR], 2.596; 95% confidence interval [CI], 1.440-4.680, \( P = .002 \)) and DFS (HR, 2.824; 95% CI, 1.667-4.783; \( P < .001 \)) (Tables 2 and 3). The results of this study implicated that ALDOA might serve as a potential biomarker for survival in clinical practice.

3.5 ALDOA knockdown inhibited proliferation and invasion of GC cells

Previous results indicated that ectopic ALDOA portended inferior clinical characteristics and shorter survival time of GC. Thus, it was hypothesized in this study that silencing the expression of ALDOA could inhibit growth and invasion of GC cells. The stable transfection models of the expression of ALDOA were established. RT-PCR and Western blot analysis were performed to verify that ALDOA transcriptional and protein levels decreased in both AGS and MGC803 cells after transfection with ALDOA-shRNA (Figure 4A,B). CCK-8 and colony formation

![Figure 5](image_url)
assays demonstrated that the proliferation of both AGS and MGC803 cells transfected with ALDOA-shRNA was significantly inactivated compared with that of those transfected with control shRNA (Figure 4C,D). Transwell assay showed that silencing the expression of ALDOA significantly inhibited the invasion of AGS and MGC803 cells (Figure 4E) \( (P < .05) \). These findings suggested that the knockdown of ALDOA repressed proliferation and invasion ability of GC cells.

### 3.6 Expression of altered ALDOA affects epithelial–mesenchymal transition induction in human GC cells

Thus, the expression of ALDOA was associated with GC metastasis and invasion ability. The capability of ALDOA to induce epithelial–mesenchymal transition (EMT) in human GC cells was subsequently investigated. The down-regulated expression of ALDOA in AGS and MGC803 cells significantly decreased the levels of vimentin, N-cadherin, Snail and ZEB1, but increased the expression of E-cadherin at both protein and transcriptional levels (Figure 5A,B). Immunofluorescence staining further revealed that E-cadherin was strongly induced while N-cadherin decreased in ALDOA-shRNA-transfected cells (Figure 5C). These results indicated that the altered expression of ALDOA affected EMT induction in GC cells.

### 3.7 ALDOA affected hypoxia-inducible factor-1α activity in GC

Hypoxia-inducible factor (HIF)-1α is critical for tumour growth and metastases, in part by inducing glycolytic enzymes and EMT process. Glycolysis is also necessary for maintaining HIF-1α activity. Therefore, it is possible that ALDOA can affect the HIF-1α activity in GC. HIF-1α acts by binding to the HIF-1α response element (HRE) upon hypoxia. Therefore, this study used HRE-luciferase reporter to examine whether ALDOA affected HRE-luciferase activities. As expected, ALDOA could increase HRE-luciferase activity in a dose-dependent manner (Figure 6A). Moreover, HRE activity could be inhibited by reducing the expression of ALDOA using its specific shRNA (Figure 6B), implying that ALDOA indeed affected the HIF-1α activity.

### 4 DISCUSSION

Great attention has been paid to glycolytic enzymes as potential therapeutic targets because the cancer-specific metabolism depends more on the glycolytic pathway than on aerobic respiration, a phenomenon called the Warburg effect. This is a novel study that characterized the importance of ALDOA in GC. First, ALDOA was screened out by performing qRT-PCR arrays of a panel of glycolysis-related genes in three paired liver metastasis tissues and primary GC tissues. Then, the clinical significance and potential mechanisms by which ALDOA mediated GC metastases and progression were explored in detail. In fact, ALDOA has been validated as an oncogene in some solid tumours. In the pancreas, it promotes tumorigenesis and progression into a highly metastatic pancreatic cancer by regulating the expression of E-cadherin. It regulates the cell cycle in non-small cell lung cancer and several solid tumours.

One of the most important findings in the present study was a direct relationship between the expression of ALDOA and the inferior clinicopathological features, and the high expression of ALDOA was an independent prognostic factor for both OS and DFS. The functional study indicated that silencing the expression of ALDOA impaired the proliferation and invasion abilities of GC cells. As EMT is the initial step of cancer metastases, the relationship between the expression of ALDOA and EMT-related marker was further validated, which suggested that ALDOA might promote tumour metastases by inducing the EMT process.

HIF-1α is critical for cancer cell survival and metastases in the solid tumour under stressed hypoxic tumour environment, in part by inducing glycolytic enzymes and EMT process. It could up-regulate a series of glycolytic genes during anaerobic glycolysis and then increase the glycolysis rate and ATP production. A previous study also suggested that glycolysis was necessary for maintaining HIF-1α activity. In the present study, the glycolytic enzyme ALDOA was also found to increase HIF-1α activity. Glycolysis and HIF-1α formed a feed-forward loop that stimulated tumour growth and metastases.
When silencing the expression of ALDOA, the anaerobic glycolysis was inhibited, ATP levels were reduced, the feed-forward loop was broken and tumour proliferation and metastases were inhibited. Conversely, the high expression of ALDOA could increase the HIF-1α activity, and HIF-1α could, in turn, promote glycolysis and EMT process. Hence, ALDOA may serve as a promising biomarker and target therapy for GC.

Several studies focused on the relationship between EMT and glycolysis. A previous study demonstrated that FBP1 was a negative regulator of EMT in GC. Loss of FBP1 by Snail-mediated repression provided metabolic advantages in basal-like breast cancer. The ectopic expression of aldolase B was associated with poor prognosis and promotes tumour progression by EMT in colorectal adenocarcinoma. Some oncogene and tumour suppressors had a crosstalk between EMT and glycolysis in cancer progression and metastases, such as HIF-1α, c-myc, FOXM1, Gas1, and so on. The present study suggested a novel function of ALDOA other than a glycolytic enzyme.

Collectively, this study provided firm evidence that ALDOA was crucial in GC by inducing the EMT pathway and affecting HIF-1α activity in tumour progression and metastasis. The expression level of ALDOA was an independent adverse prognostic factor for both OS and DFS, providing additional information for guiding therapeutic strategies.

ACKNOWLEDGEMENTS
None.

CONFLICTS OF INTEREST
None.

ORCID
Zhonghua Jiang http://orcid.org/0000-0002-7526-5877

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30.
2. Moon YW, Jeung HC, Rha SY, et al. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol. 2007;14:2730-2737.
3. Yu J, Li J, Chen Y, et al. Snail enhances glycolysis in the epithelial-mesenchymal transition process by targeting FBP1 in gastric cancer. Cell Physiol Biochem. 2017;43:31-38.
4. Galizia G, Lieto E, Auricchio A, et al. Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: a western experience. PLoS ONE. 2017;12:e0173619.
5. Gu H, Li D, Zhu H, et al. The prognostic efficacy and improvements of the 7th edition Union for International Cancer Control tumour-node-metastasis classifications for Chinese patients with gastric cancer: results based on a retrospective three-decade population study. Tumour Biol. 2017;39:1010428317694548.
6. Wang HH, Li K, Xu H, Sun Z, Wang ZN, Xu HM. Improvement of T stage precision by integration of surgical and pathological staging in radically resected stage pT3-pT4b gastric cancer. Oncotarget. 2017;8:46506-46513.
7. Peng Y, Li X, Wu M, et al. New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer. Mol BioSyst. 2012;8:3077-3088.
8. Kawai K, Uemura M, Munakata K, et al. Fructose-bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis. Int J Oncol. 2017;50:525-534.
9. Nagaraju GP, Grambhachari PV, Raghu G, El-Rayes BF. Hypoxia inducible factor-1alpha: its role in colorectal carcinogenesis and metastasis. Cancer Lett. 2015;366:11-18.
10. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5:343-354.
11. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705-713.
12. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11-20.
13. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
14. Garber K. Energy deregulation: licensing tumors to grow. Science. 2006;312:1158-1159.
15. Sanzey M, Abdul Rahim SA, Oudin A, et al. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma. PLoS ONE. 2015;10:e0123544.
16. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci. 2005;30:142-150.
17. Li Q, Li Y, Xu J, et al. Aldolase B overexpression is associated with poor prognosis and promotes tumor progression by epithelial-mesenchymal transition in colorectal adenocarcinoma. Cell Physiol Biochem. 2017;42:397-406.
18. Li J, Wang Y, Li QG, et al. Downregulation of FBP1 promotes tumor metastasis and indicates poor prognosis in gastric cancer via regulating epithelial-mesenchymal transition. PLoS ONE. 2016;11:e0167857.
19. Ji S, Zhang B, Liu J, et al. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Lett. 2016;374:127-135.
20. Zhang F, Lin JD, Zuo XY, et al. Elevated transcriptional levels of aldolase A (ALDOA) associates with cell cycle-related genes in patients with NSCLC and several solid tumors. BioData Min. 2017;10:6.
21. Zhang W, Shi X, Peng Y, et al. HIF-1alpha promotes epithelial-mesenchymal transition and metastasis through direct regulation of ZEB1 in colorectal cancer. PLoS ONE. 2015;10:e0129603.
22. Zhang L, Huang G, Li X, et al. Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1alpha in hepatocellular carcinoma. BMC Cancer. 2013;13:108.
23. Robey IF, Lien AD, Walsh SJ, Baggett BK, Gillies RJ. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia. 2005;7:324-330.
24. Grandjean G, de Jong PR, James BP, et al. Definition of a novel feed-forward mechanism for Glycolysis-HIF1alpha signaling in hypoxic tumors highlights aldolase A as a therapeutic target. Cancer Res. 2016;76:4259-4269.
25. Dong C, Yuan T, Wu Y, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013;23:316-331.
26. Ji S, Qin Y, Liang C, et al. FBW7 (F-box and WD Repeat Domain-Containing 7) negatively regulates glucose metabolism by targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) axis in pancreatic cancer. Clin Cancer Res. 2016;22:3950-3960.

27. Cui J, Shi M, Xie D, et al. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res. 2014;20:2595-2606.

28. Li Q, Qin Y, Wei P, et al. Gas1 inhibits metastatic and metabolic phenotypes in colorectal carcinoma. Mol Cancer Res. 2016;14:830-840.

How to cite this article: Jiang Z, Wang X, Li J, Yang H, Lin X. Aldolase A as a prognostic factor and mediator of progression via inducing epithelial-mesenchymal transition in gastric cancer. J Cell Mol Med. 2018;22:4377-4386. https://doi.org/10.1111/jcmm.13732